Drug intelligence / Profile preview

APB-R4

Development stage: Preclinical
Lead developer: Aprilbio
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

APB-R4 is a preclinical-stage interleukin-2 receptor (IL-2R) agonist and immunomodulator developed by Aprilbio. It is designed to modulate the immune system by targeting the IL-2 receptor, with potential applications in immune-related therapeutic areas such as autoimmune and inflammatory diseases. The drug utilizes Aprilbio's proprietary SAFA (Serum Albumin Fragment Associated) platform technology, which involves fusing a therapeutic protein to an anti-serum albumin antibody fragment to extend its half-life and improve therapeutic efficacy.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on APB-R4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APB-R4.

Explore the full profile